BC Week In Review | Oct 26, 2015
Clinical News

CriPec docetaxel: Phase I started

Cristal began an open-label, European Phase I trial to evaluate CriPec docetaxel in patients with solid tumors. Cristal Therapeutics , Maastricht, the Netherlands   Product: CriPec docetaxel   Business: Cancer   Molecular target: NA   Description:...
BioCentury | Jun 24, 2013
Emerging Company Profile

Cristal: Tunable nanoparticles

Cristal Therapeutics aims to improve the therapeutic profile of drugs by entrapping them within biodegradable polymeric nanoparticles. While the company's CriPec platform has several characteristics in common with other polymer-based nanoparticle carriers, it may be...
Items per page:
1 - 2 of 2